EXECUTIVE ENGAGEMENTS
OUTREACH
5611
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
898
Interactions with Platform & by Email
PARTICIPANTS
168
Unique # Participated
VALIDATIONS
36
Responses Validated*
COMPETITORS
42
Responses Validated*
* Login for a full stack data experience
DATE
APR 2021
TABLES
66
PAGES
138
EDITION
9
PRICE
USD 4950
*Engagement stats are ongoing and dynamic
HIGHLIGHTS
Amid the COVID-19 crisis, the global market for Heart Failure Drugs estimated at US$5 Billion in the year 2020, is projected to reach a revised size of US$11.3 Billion by 2027, growing at a CAGR of 12.4% over the period 2020-2027.
The Heart Failure Drugs market in the U.S. is estimated at US$1.3 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.5 Billion by the year 2027 trailing a CAGR of 16.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.7% and 10.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 9.7% CAGR.
SELECT PLAYERS
AstraZeneca PLC; Bayer AG; Boehringer Ingelheim (Canada) Ltd.; Bristol-Myers Squibb Company; CRC Health; Exelixis, Inc.; GlaxoSmithKline plc; Johnson & Johnson; Lunan Pharmaceuticals Co. Ltd.; Merck & Co., Inc.; Mylan N.V.; Novartis AG; Pfizer, Inc.; Sanofi S.A.; Shanghai Haini Pharmaceutical Co., Ltd.; Shanghai Xudong Haipu Pharmaceutical Co., Ltd.; The National Council for Palliative Care; Valeant Pharmaceuticals International, Inc.
SEGMENTS
» Segment (Heart Failure Drugs)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » Spain » Russia » and Rest of Europe » Asia-Pacific » Australia » India » South Korea » and Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » and Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » United Arab Emirates » and Rest of Middle East » and Africa
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Current & Future Analysis for Heart Failure Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Heart Failure Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Heart Failure Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| USA Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| CANADA |
| Canada Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| JAPAN |
| Japan Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| CHINA |
| China Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| EUROPE |
| Europe Current & Future Analysis for Heart Failure Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Heart Failure Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Heart Failure Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027 |
| FRANCE |
| France Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| GERMANY |
| Germany Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| ITALY |
| Italy Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UNITED KINGDOM |
| UK Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| SPAIN |
| Spain Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Spain Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| RUSSIA |
| Russia Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Russia Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| REST OF EUROPE |
| Rest of Europe Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| ASIA-PACIFIC |
| Asia-Pacific Current & Future Analysis for Heart Failure Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Heart Failure Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Heart Failure Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027 |
| AUSTRALIA |
| Australia Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Australia Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| INDIA |
| India Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| India Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| SOUTH KOREA |
| South Korea Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| South Korea Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| REST OF ASIA-PACIFIC |
| Rest of Asia-Pacific Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Asia-Pacific Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| LATIN AMERICA |
| Latin America Current & Future Analysis for Heart Failure Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Latin America Historic Review for Heart Failure Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Latin America 15-Year Perspective for Heart Failure Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027 |
| ARGENTINA |
| Argentina Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Argentina Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| BRAZIL |
| Brazil Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Brazil Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| MEXICO |
| Mexico Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Mexico Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| REST OF LATIN AMERICA |
| Rest of Latin America Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Latin America Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| MIDDLE EAST |
| Middle East Current & Future Analysis for Heart Failure Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Middle East Historic Review for Heart Failure Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Middle East 15-Year Perspective for Heart Failure Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027 |
| IRAN |
| Iran Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Iran Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| ISRAEL |
| Israel Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Israel Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| SAUDI ARABIA |
| Saudi Arabia Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Saudi Arabia Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UNITED ARAB EMIRATES |
| UAE Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UAE Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| REST OF MIDDLE EAST |
| Rest of Middle East Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Middle East Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| AFRICA |
| Africa Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Africa Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| IV. COMPETITION |
| Total Companies Profiled: 42 |
China Has Risen Into An Economic Powerhouse.
Find Out How You Can Leverage This Opportunity!
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com